Abcam, ab222395, Anti-Cdk6 antibody [EPR4515] - BSA and Azide free

Size: 100µg / 1mg
Knockout Tested Rabbit Recombinant Monoclonal CDK6 antibody. Carrier free. Suitable for IHC-P, ICC/IF, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 6 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR4515,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:Flow Cyt (Intra), ICC/IF, WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.,
Specificity:Based on the immunogen sequence, we do not expect the antibody to cross-react with other CDK family members. No cross-reactivity testing has been performed.

Product details:
ab222395 is the carrier-free version of
ab124821
Species reactivity
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species.
Please
contact us
for more information.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cdk6 also known as Cyclin-dependent kinase 6 is a protein kinase involved in the regulation of the cell cycle. It has a molecular weight of approximately 40 kDa. Cdk6 is expressed in various tissues including lymphoid tissues and the brain. It plays a mechanical role by phosphorylating target proteins which impacts cell cycle progression particularly during the transition from G1 phase to S phase. Cdk6 can work in conjunction with D-type cyclins to form a complex that is critical for its activity.
Biological function summary
Cdk6 functions as a regulator of the cell cycle. It participates in a complex with cyclin D to control the G1 phase progression. This activity is essential for the regulation of cell division and proliferation. The association with cyclin D allows Cdk6 to phosphorylate the retinoblastoma protein (Rb) leading to the release of E2F transcription factors that promote the expression of genes necessary for DNA synthesis.
Pathways
Cdk6 is an important component of the cell cycle control pathway. It interacts primarily with the retinoblastoma protein and Cyclin D1 in this context. The cell cycle pathway is critical for controlled cell proliferation and its dysregulation can lead to diseases like cancer. Another involved pathway is the PI3K/AKT pathway which can activate Cdk6 activity through upstream signaling events implicating Cdk6 in cellular responses to growth signals.
Cdk6 has a significant role in cancer development due to its involvement in uncontrolled cell proliferation. Its overexpression or dysregulation is often linked to cancers such as leukemia and glioblastoma. In cancer the interaction with proteins like cyclin D1 can lead to unchecked progression through the cell cycle contributing to oncogenesis. Additionally Cdk6 inhibitors are being explored as therapeutic agents in cancer treatment due to their potential to restore control over cell cycle progression.